Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free public preview Track APGE with free AI briefings, catalyst countdowns, and dilution alerts.

APGE — Apogee Therapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$451.8M Cash on Hand
22.9mo Cash Runway
22% Short Interest

🧪 Upcoming Trial Catalysts

📊 Drug Pipeline

DrugIndicationPhaseStatus
APG777 Atopic Dermatitis PHASE2 ACTIVE_NOT_RECRUITING
APG990 Atopic Dermatitis PHASE1 ACTIVE_NOT_RECRUITING
Dupilumab Atopic Dermatitis PHASE1 ACTIVE_NOT_RECRUITING

💰 Cash Runway & Dilution Risk

APGE holds $451.8M in cash and burns about $59.1M/quarter from operations, giving an estimated runway of 22.9 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for APGE free →

📈 Recent Insider Activity (Form 4)

DateInsiderTypeValue
2026-06-12 HENDERSON MICHAEL THOMAS
Sale $91.2M
2026-06-12 HENDERSON MICHAEL THOMAS
Sale $91.2M
2026-06-12 HENDERSON MICHAEL THOMAS
Sale $92.6M
2026-06-12 HENDERSON MICHAEL THOMAS
Sale $93.6M
2026-06-12 HENDERSON MICHAEL THOMAS
Sale $94.6M

Get the full APGE picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for APGE and 2 more tickers of your choice.

Create Free Account →
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.